Front Oncol. 2023 Oct 18:13:1131803.doi: 10.3389/fonc.2023.1131803. eCollection 2023.

本文采用的英格恩产品: 增强型ECL发光液

RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy

Affiliations

Affiliations

  • 1 Department of Oncology, Baotou Central Hospital, Inner Mongolia Medical University, Baotou, China.
  • 2 Department of Oncology, Baotou Central Hospital, Baotou, China.
  • 3 Institute of Translational Medicine, Baotou Central Hospital, Baotou, China.

Free PMC article

Abstract

Cervical carcinoma (CC) is the one of most common gynecologic cancers worldwide. The ribosomal proteins (RPs) are essential for ribosome assembly and function, and it has been verified that the abnormal expression of RPs was closely associated with tumorigenesis. In this study, we found that the RP large subunit 24 (RPL24) expression level was upregulated after the CC cell lines SiHa and HeLa were treated with Cisplatin (CDDP) in vitro. Simultaneously, a nude mouse xenograft model was used to examine the effect of RPL24 on tumor growth in vivo, which showed that overexpression of RPL24 can suppress tumor growth. Furthermore, we proved that RPL24 expression increased after CC patients were treated with concurrent chemoradiotherapy (CCRT), and the higher expression of RPL24 predicted a better prognosis using clinical data from 40 CC patients, verified via the Kaplan-Meier Plotter and LOGpc. These results revealed that RPL24 can be considered a potential biomarker to predict the prognosis of CC patients and assess CCRT efficacy.

Keywords: RPL24; biomarker; cervical cancer; concurrent chemoradiotherapy; prognosis.

在线客服
在线客服
热线电话
 
0
    0
    我的购物车
    购物车是空的去下单